Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Modelling study based on a single trial's survival data, assessing cost-effectiveness in a specific healthcare system; does not itself evaluate clinical outcomes and depends on external trial evidence and assumptions.
A rigorous health economic analysis based on a pivotal Phase 3 RCT (KEYNOTE-689) with clear cost-effectiveness results well below the Swiss willingness-to-pay threshold, though grounded in modelling rather than direct trial cost outcomes.
Single-center mechanistic study with small sample size (n=4 for single-cell analysis) characterizing HPV-specific T-cell populations; functional validation of TCRs supports hypothesis but lacks clinical endpoint data or comparative outcome analysis.